Clinical Trials
11
4 active
Approvals
537
Total approvals
Agencies
2
Regulatory bodies
Founded
N/A
Active, not recruiting
4
36.4%
Completed
4
36.4%
Recruiting
3
27.3%
- Chandigarh University's biotechnology and pharmaceutical sciences programs placed 178 students and secured 261 industry internships over three years with companies including Sun Pharma, GSK, and Serum Institute of India. - The University Institute of Biotechnology contributed 118 placements, with MSc Biotechnology recording the highest selections at 59 students and the top salary package reaching ₹8 lakh annually. - The University Institute of Pharmaceutical Sciences achieved 60 placements, with a Pharm.D student securing the highest package of ₹9.6 LPA at Karuna Cancer Hospital. - Students have also achieved international academic success, published over 40 research papers, and founded startups including Nutripanda Life Care LLP and Nubody&CO.
- Sun Pharma will present updated long-term follow-up data for UNLOXCYT (cosibelimab-ipdl) in locally advanced cutaneous squamous cell carcinoma at ASCO 2026, representing the second largest prospective study of its kind. - The study demonstrated a 50% objective response rate with 27% complete responses in 64 patients, with median duration of response not yet reached after over 31 months of follow-up. - The treatment showed a manageable safety profile with only one patient experiencing Grade ≥3 immune-related adverse events, supporting its use in elderly patients with multiple comorbidities. - UNLOXCYT is indicated for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.
- Sun Pharma Advanced Research Company's licensing partner Ocuvex Therapeutics received a Complete Response Letter from the FDA for glaucoma drug PDP-716, preventing immediate approval. - The FDA cited inspection findings at the finished product manufacturing facility as the sole reason for the regulatory setback, with no other issues identified. - The delay prevents PDP-716 from entering the U.S. market until manufacturing facility issues are resolved and the FDA re-evaluates the application. - Sun Pharma ARC shares fell 10.82% following the regulatory announcement, reflecting investor concerns about potential revenue impact and delayed market entry.
- Sun Pharma voluntarily recalled a single batch of 675 vials of Doxorubicin Hydrochloride Liposome Injection after detecting glass particles during production. - The FDA warns that glass particles administered intravenously pose serious safety risks including blood vessel blockage and life-threatening blood clot events. - The recalled cancer treatment drug is used for ovarian cancer, AIDS-related Kaposi sarcoma, and multiple myeloma with an expiration date of May 31, 2027. - No adverse incidents have been reported to date, and Sun Pharma is arranging product returns and replacements through express overnight mail.
- Sun Pharma Advanced Research Company (SPARC) has entered into a definitive asset purchase agreement to sell its rare pediatric disease priority review voucher for $195 million to an undisclosed buyer. - The voucher was granted by the FDA following approval of Sezaby, SPARC's medication indicated for the treatment of neonatal seizures. - SPARC CEO Anil Raghavan stated the sale will enable acceleration of pipeline asset development and strengthen the company's external innovation strategy. - The Priority Review Voucher program incentivizes development of treatments for rare pediatric diseases by allowing expedited review of future drug applications.
- Sun Pharma's partner Philogen reported that Phase II trials for Fibromun in soft tissue sarcoma and glioblastoma failed to meet primary endpoints, though survival improvements were observed in select patient subgroups. - Despite setbacks, the company is advancing toward Phase III registrational trials for Fibromun, with FIBROSARC-2 study design being finalized through FDA and EMA scientific advice. - Nidlegy demonstrated stronger clinical progress in skin cancers, with 52.60% complete pathological response rates in basal cell carcinoma and multiple registrational studies planned for 2026. - The mixed results highlight the challenges of developing therapies for complex oncology indications while showing promise in specific patient populations and alternative cancer types.
- Sun Pharma Advanced Research Company (SPARC) is implementing a major restructuring to achieve $10 million in annual cost savings while managing $46 million in debt and consolidating operations in Vadodara. - The company is reducing its workforce by 40% to 246 employees by FY27 and cutting R&D spending from $20.4 million to $14.3 million in FY25 while focusing on high-value oncology and immunology assets. - Lead oncology candidate SBO-154, an anti-MUC1-SEA antibody drug conjugate, is advancing through Phase 1a dose escalation targeting multiple cancer types with maximum tolerated dose readout expected by Q4 2026. - Immunology asset SCD-153, a first-in-class topical itaconate prodrug for alopecia areata and vitiligo, completed Phase 1b cohort 1 with topline results anticipated in Q4 2026.
- The FDA announced a nationwide recall of lisdexamfetamine dimesylate capsules, a generic form of Vyvanse, on October 28 due to failed dissolution tests. - The recalled medication cannot deliver optimal therapeutic levels, potentially impacting treatment efficacy for ADHD patients across multiple dosage strengths. - Sun Pharmaceutical Industries shipped the affected lots between May 2024 and November 2024, with patients advised to contact healthcare providers for replacements. - While the dissolution failure compromises therapeutic effectiveness, officials confirm the recalled medication poses no safety or health risks to patients.
- Sun Pharma's experimental oral drug SCD-044 (Vibozilimod) failed to meet primary endpoints in Phase 2 trials for both psoriasis and atopic dermatitis, missing the 75% improvement target in PASI and EASI scores at 16 weeks. - The company has discontinued further clinical development of SCD-044, which was considered one of the more promising assets in SPARC's specialty pipeline for inflammatory disorders. - SPARC shares plunged 19% following the disappointing results, while Sun Pharma and its R&D arm will reassess the compound's future despite the drug being generally safe and well tolerated.
